Zug, Switzerland, September 25, 2015 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a corporate symposium at the Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF).[1] The symposium on "Rational Pharmacotherapy for Acute Hearing Loss - Recent Advances and Perspectives" will take place on September 28, 2015, at 6.15 p.m. CDT at the Omni Hotel in Dallas TX.
The symposium will be chaired by Lawrence R. Lustig, MD, Howard W. Smith Professor and Chairman of the Department of Otolaryngology Head and Neck Surgery at the Columbia University Medical Center, New York. The program will feature talks on:
- Hearing Preservation Following Acute Cochlear Stress Injury; Adrien E. Eshraghi, MD, University of Miami Ear Institute
- Drug Delivery to the Inner Ear; Hinrich Staecker, MD, PhD, University of Kansas Medical Center
- Clinical Trials in Acute Hearing Loss; Steven D. Rauch, MD, Harvard Medical School
- Efficacy Outcomes in Hearing Loss Clinical Trials; Christopher F. Halpin, PhD, Harvard Medical School
Webcasts of the presentations will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com) within 48 hours after the event.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.
